Researchers in China identified independent prognostic indicators for gastrointestinal stromal tumors (GISTs) and published their findings in Medicine. This knowledge may improve accurate risk assessments and allow the use of individualized therapies and better follow-up strategies for patients. There are many factors affecting the prognosis of GISTs but the main ones are the tumor stage…
Researchers presented the cases of 2 patients with gastrointestinal stromal tumors (GISTs) caused by novel germline variants in SDBH and KIT respectively, and published their findings in the Clinical Journal of Gastroenterology. Around 80% of GISTs are characterized by activating KIT mutations and around 7% to 8% have PDGFRA mutations. As for the remaining cases…
Aerovate Therapeutics has announced results of their phase 1 trial of AV-101, a new dry powder inhaled imatinib formulation for the treatment of patients with pulmonary arterial hypertension (PAH). The results were presented at the American Thoracic Society (ATS) International Conference in San Francisco, California on May 16, 2022. “We are pleased these Phase 1…
Researchers from China developed a new model to predict secondary imatinib-resistant gastrointestinal stromal tumors (GISTs). Bioinformatic mining results of the study “provide potential and promising targets for imatinib-resistant therapy,” they said in a study published in the Scandinavian Journal of Gastroenterology. Imatinib is a drug that inhibits KIT signaling, which is involved in the pathogenesis…
Inhaled seralutinib improved cardiopulmonary hemodynamics and inflammatory biomarkers, reduced N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels, and reversed remodeling of the pulmonary vasculature in 2 animal models of pulmonary arterial hypertension (PAH). The treatment was found to be more effective than imatinib. These results were published in the European Respiratory Journal. “We are excited to…
Treatment with adjuvant imatinib for 3 years, which is the current standard of care for patients with high-risk gastrointestinal stromal tumors (GISTs), is generally well-tolerated and effective, according to a new study published in the International Journal of Cancer. This finding is consistent with the clinical outcomes of previous reports. Factors associated with poor recurrence-free…
Tenax Therapeutics has announced that its modified formulation of imatinib mesylate, TNX-201, effectively preserves bioavailability while minimizing gastric release in pulmonary arterial hypertension (PAH). The pharmacokinetic results, announced via news release, showed that TNX-201 bioavailability significantly exceeded Tenax’s relative bioavailability threshold as compared with Gleevec® tablets as reference. “Since it has been established that oral…
Olverembatinib leads to a clinical benefit rate of 83.3% in patients with gastrointestinal stromal tumors (GISTs) who were resistant to or failed prior treatment with tyrosine kinase inhibitors, according to results from a phase 1b/2 clinical trial presented at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting. The open-label, multicenter trial evaluated the…
Neoadjuvant imatinib can cause significant shrinkage of gastric gastrointestinal stromal tumors (GISTs), thus facilitating the minimally invasive resection of the tumor, according to a study published in Annals of Surgical Oncology. The current treatment for localized GISTs is surgical resection. Studies have validated the use of adjuvant imatinib for patients who are at high risk…
Treatment with imatinib appears to improve outcomes for patients with gastrointestinal stromal tumors (GISTs) with rectal tumors, according to a study published in BJS Open. Patients with GISTs in the study who received neoadjuvant imatinib had a median 30% (range, 0 to -56%) reduction in tumor size prior to resection surgery. The reduction in size…
